Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Companyâs T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
髿é·
å瀟ã®åçã¯éå»3幎éã«ãããçå®ã«å¢å ããŠããã幎平åã§1308.75%ã®æé·çã瀺ããŠããŸãã
é»å転æ
å瀟ã¯é»å転æãæãããææ°ã®å¹ŽéçŽå©çã¯USD ã§ãã
å²å®
åç€Ÿã®ææ°ã®PEã¯-5.93ã§ãéå»3幎éã®æ°Žæºãšæ¯èŒããŠå®å€åã«ãããŸãã
æ©é¢æè³å®¶ã®å£²ãè¶ã
ææ°ã®æ©é¢æè³å®¶ã®ä¿ææ ªæ°ã¯3.70Mæ ªã§ãåååææ¯ã§14.85%æžå°ããŠããŸãã
ã¹ãã£ãŒãã³ã»ã³ãŒãšã³ãä¿æ
ã¹ã¿ãŒæè³å®¶ã¹ãã£ãŒãã³ã»ã³ãŒãšã³ã¯æ¬éæã87.18Kæ ªä¿æããŠããŸãã
åžå ޿޻åãäœèª¿
å瀟ãžã®æè³å®¶ã®é¢å¿ã¯äœäžããŠããã20æ¥éã®å£²è²·å転çã¯-0.76ã§ãã